Financial Results & Limited Review for June 30, 2015
Omkar Speciality Chemicals Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended June 30, 2015.17-07-2015
Financial Results & Limited Review for June 30, 2015
Omkar Speciality Chemicals Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended June 30, 2015.Shareholding Pattern For June 30, 2015
Omkar Speciality Chemicals Ltd has informed BSE about the Shareholding Pattern as on June 30, 2015.Closure of Trading Window
Omkar Speciality Chemicals Ltd has informed BSE that the meeting of Board of Directors of the Company will be held on July 17, 2015, inter alia, to consider and approve the Un-Audited Financial Results for the Quarter ended on June 30, 2015.Further, as per SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Code of Conduct adopted by the Company, the 'Trading Window' for trading in the Company's securities shall remain closed...Update - Omkar Speciality Chemicals Ltd has filed a Patent application for precursor of latest Hepatitis C Drug
Omkar Speciality Chemicals Ltd has informed BSE that the Company has filed one more application for the grant of Patent for preparing 4-BROMO-ORTHO-PHENYLENE-DIAMINE, a key precursor for making of the drug namely Ledipasvir. Ledipasvir is a drug for the treatment of Hepatitis C.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
P S Herlekar has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSERevised Financial Results for March 31, 2015
Omkar Speciality Chemicals Ltd has informed BSE about the Financial Results for the period ended March 31, 2015.Financial Results for March 31, 2015 (Audited)
Omkar Speciality Chemicals Ltd has informed BSE about the Financial Results for the period ended March 31, 2015.Outcome of Board Meeting
Omkar Speciality Chemicals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2015, inter alia, has discussed and approved the following:1. The Board of Directors has recommended for formulating the scheme of Employee Stock Option Plan (ESOP) named as OSCL ESOP 2015, subject to the approvals of the concerned regulatory authorities and the members of the Company....Board recommends Dividend
Omkar Speciality Chemicals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2015, inter alia, has recommended a dividend of Rs. 1.50 (15%) per Equity Share of Rs. 10 each for the Financial Year ended on March 31, 2015.